The primary objective of this study is to compare the multiple dose bioavailability of ICN and Schering-Plough ribavirin capsules in compensated chronic hepatitis C in conjunction with interferon alpha-2b. The secondary objective is to assess patient variability with regard to pharmacokinetics of each ribavirin capsule formulation. This clinical trial continues and no preliminary results are available.
Showing the most recent 10 out of 871 publications